Unlike many other viruses, HIV-1 is highly variable. The structure of the viral envelope
changes as the infection progresses and is one of the biggest obstacles in developing an …

Individuals infected with HIV-1 and nearly everyone vaccinated with HIV-1 vaccines will, in
time, generate antibodies against viral proteins. These antibodies do not resolve natural …

Neutralizing and other antiviral antibodies in HIV-1 infecti... : Current Opinion in HIV and AIDS
Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination : Current Opinion …

Broadly neutralizing antibodies represent the major protective mechanism of vaccines
targeting pathogenic microbes in humans and animals. For HIV, broadly neutralizing …

The holy grail of human immunodeficiency virus (HIV) vaccine development is an
immunogen that elicits antibodies that neutralize field strains of the virus. In recent years, we …

Infection with human immunodeficiency virus type 1 (HIV-1) generates cellular and humoral
immune responses of various magnitudes to multiple virus-specific antigens. Perhaps the …

The field of HIV-1 vaccine research has seen a renaissance with the identification of
antibodies that neutralize most circulating HIV-1 strains. An understanding of the structural …

Role of nonneutralizing antibodies in vaccines and/or HIV in... : Current Opinion in HIV and
AIDS Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals : Current …

It is common parlance to refer to viral antigens and their epitopes as immunogens capable of
producing antibodies (Abs) against the virus that harbours them. Words have an insiduous …

Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies
are broadening the spectrum of pre-and post-exposure treatment against HIV-1. A better …